158 results on '"Chappey, Colombe"'
Search Results
2. Neutralizing Antibody Responses Drive the Evolution of Human Immunodeficiency Virus Type 1 Envelope during Recent HIV Infection
3. Evidence for Positive Epistasis in HIV-1
4. Supplementary Data from A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)
5. Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors
6. Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors
7. Phenotypic Susceptibility to Didanosine Is Associated with Antiviral Activity in Treatment-Experienced Patients with HIV-1 Infection
8. Comparison of standard PCR/cloning to single genome sequencing for analysis of HIV-1 populations
9. Broad Nucleoside Reverse-Transcriptase Inhibitor Cross-Resistance in Human Immunodeficiency Virus Type 1 Clinical Isolates
10. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism
11. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection
12. Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information
13. Abstract P1-19-03: JAVELIN PARP Medley, a phase 1b/2 study of avelumab plus talazoparib: Results from advanced breast cancer cohorts
14. Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, Uganda
15. Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance
16. A web-based genotyping resource for viral sequences
17. Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance
18. JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti–PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect.
19. A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)
20. Diversity of the V3 region of HIV in Paris, France
21. Cn3D: sequence and structure views fo Entrez
22. Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO).
23. Abstract A017: PD-L1 as a predictive biomarker for atezolizumab (MPDL3280A; anti-PDL1) in non-small cell lung cancer (NSCLC)
24. Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)
25. Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1–selected patients with non-small cell lung cancer (NSCLC).
26. Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study.
27. Safety, virology and pharmacokinetics of oseltamivir in infants with laboratory-confirmed influenza: a Phase I/II, prospective, open-label, multi-centre clinical trial
28. Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC).
29. Safety, Tolerability, and Pharmacokinetics of Intravenous Oseltamivir: Single- and Multiple-Dose Phase I Studies with Healthy Volunteers
30. A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase
31. Differences in Reversion of Resistance Mutations to Wild-Type under Structured Treatment Interruption and Related Increase in Replication Capacity
32. Principal component analysis of general patterns of HIV-1 replicative fitness in different drug environments
33. An Evolutionary Model-Based Algorithm for Accurate Phylogenetic Breakpoint Mapping and Subtype Prediction in HIV-1
34. Human Immunodeficiency Virus Type 1 Protease-Correlated Cleavage Site Mutations Enhance Inhibitor Resistance
35. Quantitation of HER2 Expression or HER2:HER2 Dimers and Differential Survival in a Cohort of Metastatic Breast Cancer Patients Carefully Selected for Trastuzumab Treatment Primarily by FISH
36. Prevalence, Genotypic Associations and Phenotypic Characterization of K65R, L74V and other HIV-1 RT Resistance Mutations in a Commercial Database
37. Response to comment on 'Evidence for positive epistasis in HIV-1'
38. Development of an HIV-1 Reference Panel of Subtype B Envelope Clones Isolated From the Plasma of Recently Infected Individuals
39. Development and Characterization of a Novel Single-Cycle Recombinant-Virus Assay To Determine Human Immunodeficiency Virus Type 1 Coreceptor Tropism
40. Differential Impact of Thymidine Analogue Mutations on Emtricitabine and Lamivudine Susceptibility
41. Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus
42. The K101P and K103R/V179D Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Resistance to Nonnucleoside Reverse Transcriptase Inhibitors
43. Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Variation and Neutralizing Antibody Responses during Transmission of HIV-1 Subtype B
44. Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies
45. Analysis of Transition from Long-Term Nonprogressive to Progressive Infection Identifies Sequences that May Attenuate HIV Type 1
46. Safety, Virology and Pharmacokinetics of Oseltamivir in Infants with Laboratory-Confirmed Influenza: A Phase I/II, Prospective, Open-Label, Multicentre Clinical Trial
47. Molecular Characterization and Phylogenetic Analyses of a New Simian T Cell Lymphotropic Virus Type 1 in a Wild-Caught African Baboon (Papio anubis) with an Indeterminate STLV Type 2-Like Serology
48. Selective pressure exerted by immunodominant HIV-1-specific cytotoxic T lymphocyte responses during primary infection drives genetic variation restricted to the cognate epitope
49. Characterization of Mother-Infant HIV Type 1 gag p17 Sequences Associated with Perinatal Transmission
50. Simian T-Cell Lymphotropic Virus Type 1 from Mandrillus sphinx as a Simian Counterpart of Human T-Cell Lymphotropic Virus Type 1 Subtype D
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.